Literature DB >> 3162631

Approaches to assessing the rationality of drug usage in a developed country.

G Boëthius1.   

Abstract

The prerequisites for analyses of the medical, social and economic consequences of drug usage are in part available in Sweden. Hard data, though, are still fragmentary. Examples are given where various data sources and methods have been applied. It is suggested that feedback of drug utilization data should increase to create a more questioning attitude among prescribers. The concept of medical audit has to be better explained including the fact that individual-based registers are necessary tools in trying to assess the rationality of drug treatment. In the future such analyses should focus on everyday treatment of common disease entities such as hypertension, diabetes, dyspepsia and asthma. Long term medical and economical consequences of optimized pharmacological versus non-pharmacological treatment should be studied.

Entities:  

Mesh:

Year:  1988        PMID: 3162631     DOI: 10.1111/j.0954-6820.1987.tb05373.x

Source DB:  PubMed          Journal:  Acta Med Scand Suppl        ISSN: 0365-463X


  5 in total

1.  Comparison of prescribing habits of general practitioners in The Netherlands versus England and Wales.

Authors:  F M Hull; R F Westerman; R Jonkers
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

Review 2.  Drug utilisation studies as tools in health economics.

Authors:  J A Sacristán; J Soto
Journal:  Pharmacoeconomics       Date:  1994-04       Impact factor: 4.981

3.  The defined daily dose as a tool in pharmacoeconomics. Advantages and limitations.

Authors:  K W Clarke; D Gray
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

4.  Patients, doctors and their drugs. A study at four levels of health care in an area of Sri Lanka.

Authors:  G Tomson; I Angunawela
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Common genetic risk variants identified in the SPARK cohort support DDHD2 as a candidate risk gene for autism.

Authors:  Hyejung Won; Jason L Stein; Nana Matoba; Dan Liang; Huaigu Sun; Nil Aygün; Jessica C McAfee; Jessica E Davis; Laura M Raffield; Huijun Qian; Joseph Piven; Yun Li; Sriam Kosuri
Journal:  Transl Psychiatry       Date:  2020-08-03       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.